A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Kim Linton

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Kim Linton

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

78 Downloads (Pure)

Original language	English
Pages (from-to)	5210
Journal	Blood
Volume	130
Publication status	Published - Dec 2017

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Eyre__www.bloodjournal.org_content_130_Suppl_1_5210Final published version, 416 KB

Cite this

@article{db6563da03934556b512d5a26ca5c11e,

title = "A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)",

author = "Kim Linton",

year = "2017",

month = dec,

language = "English",

volume = "130",

pages = "5210",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

}